OTCMKTS:PPCB

Propanc Biopharma (PPCB) Stock Forecast, Price & News

$0.03

0.00 (0.00%)

(As of 09/20/2023 ET)

Compare

Today's Range: $0.02
▼
$0.03
50-Day Range: $0.03
▼
$0.12
52-Week Range: $0.02
▼
$0.26

Volume: 147,557 shs
Average Volume: 465,356 shs
Market Capitalization: $88,447.20

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Financials Headlines SEC Filings Short Interest

About Propanc Biopharma (OTCMKTS:PPCB) Stock

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

PPCB Price History

30 days | 90 days | 365 days | Advanced Chart

PPCB Stock News Headlines

August 15, 2023 | finance.yahoo.com

Propanc Biopharma Targets Site of First-In-Human Study for PRP at the Peter Mac Cancer Center, Melbourne, Australia

July 26, 2023 | finance.yahoo.com

Propanc Biopharma’s Clinical Candidate PRP Targeting Pancreatic Cancer Market Forecast to Reach $6.93 Billion by 2030

September 21, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

July 13, 2023 | finance.yahoo.com

Propanc Biopharma Peer Reviewed Scientific Article Reaches 3,000 Reads

July 5, 2023 | finance.yahoo.com

Propanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors

June 30, 2023 | sg.finance.yahoo.com

PPCB - Propanc Biopharma, Inc.

June 28, 2023 | finance.yahoo.com

PROPANC BIOPHARMA INC (PPCB) stock forecast and price target

May 25, 2023 | finance.yahoo.com

Propanc Biopharma’s Intellectual Property Portfolio Makes Important Advancements in Europe

September 21, 2023 | Chaikin Analytics (Ad)

This Stock Could Go Up 66% or More.

Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.

May 23, 2023 | finance.yahoo.com

Propanc Biopharma’s Intellectual Property Portfolio Achieves Significant Milestones in North America

May 23, 2023 | finance.yahoo.com

Propanc Biopharma Announces Reverse Stock Split

March 28, 2023 | finance.yahoo.com

Propanc Biopharma Announces That PRP Suppresses TGF-β Pathway & Tumor Microenvironment in Pancreatic Cancer

March 16, 2023 | finance.yahoo.com

Propanc Biopharma Confirms PRP Exerts Significant Effects Against Chemoresistant Pancreatic Tumor Cells

March 14, 2023 | benzinga.com

Xeris Biopharma Holdings Stock (NASDAQ:XERS), Analyst Ratings, Price Targets, Predictions

February 23, 2023 | seekingalpha.com

PPCB Propanc Biopharma, Inc.

January 11, 2023 | finance.yahoo.com

Propanc Biopharma’s Joint Researcher Presents at the 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC)

December 17, 2022 | finanznachrichten.de

Propanc Biopharma, Inc.: Propanc Biopharma's Joint Researcher Receives Award at Doctoral Conference at the University of Jaén

December 15, 2022 | finance.yahoo.com

Propanc Biopharma’s Joint Researcher Receives Award at Doctoral Conference at the University of Jaén

November 30, 2022 | finance.yahoo.com

Propanc Biopharma Concludes PRP Could Become an Effective Chemosensitizer Agent Against Pancreatic Cancer

November 15, 2022 | finance.yahoo.com

Propanc Biopharma’s CSO Predicts PRP Could Enhance Therapeutic Effects of Immune Checkpoint Therapy for Pancreatic Cancer

October 26, 2022 | finance.yahoo.com

Propanc Biopharma’s CEO to Present at Sidoti & Company Micro-Cap Virtual Investor Conference

October 12, 2022 | finance.yahoo.com

Propanc Biopharma’s CEO to Attend 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC), Dec 15 - 17

September 29, 2022 | finance.yahoo.com

Propanc Biopharma Targets Pancreatic & Ovarian Cancers for PRP Clinical Studies with Combined Markets to Reach Over $14.3 Billion by 2027

September 8, 2022 | finance.yahoo.com

Propanc Biopharma Reports Significant Effects of PRP Against the Tumor Microenvironment

August 23, 2022 | finance.yahoo.com

Propanc Biopharma Synthesizes Recombinant Trypsinogen & Chymotrypsinogen Via POP1 Joint Research & Drug Discovery Program

August 17, 2022 | finanznachrichten.de

Propanc Biopharma, Inc.: Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent Office

August 16, 2022 | finance.yahoo.com

Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent Office

See More Headlines

Receive PPCB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Propanc Biopharma and its competitors with MarketBeat's FREE daily newsletter.

PPCB Company Calendar

Today: 9/21/2023
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:PPCB
CUSIP: N/A
CIK: 1517681
Web: www.propanc.com
Phone: (139) 882-0780
Fax: 61 03 9882 9969
Employees: 1
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-2,660,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -2,634.75%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.03
Quick Ratio: 0.03

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($13.75) per share
Price / Book: 0.00

Miscellaneous

Outstanding Shares: 3,288,000
Free Float: 3,229,000
Market Cap: $88,447.20
Optionable: Not Optionable
Beta: 1.59

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Mr. James Nathanielsz (Age 49)
Exec. Chairman, CEO, CFO, Treasurer & Sec.
Comp: $349.38k

Dr. Julian Norman Kenyon ChB (Age 75)
M.D., MB, Chief Scientific Officer, CTO & Director
Comp: $35.99k

Prof. Klaus Kutz
Chief Medical Officer & Member of Scientific Advisory Board

Key Competitors

View All Competitors

PPCB Stock - Frequently Asked Questions

How have PPCB shares performed in 2023?: Propanc Biopharma's stock was trading at $0.60 at the beginning of 2023. Since then, PPCB shares have decreased by 95.5% and is now trading at $0.0269.
View the best growth stocks for 2023 here.
When did Propanc Biopharma's stock split?: Propanc Biopharma shares reverse split before market open on Tuesday, May 23rd 2023. The 1-1000 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.
What other stocks do shareholders of Propanc Biopharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Propanc Biopharma investors own include Avis Budget Group (CAR), Cronos Group (CRON), CRISPR Therapeutics (CRSP), Petroteq Energy (PQEFF), Xerox (XRX), Aurora Cannabis (ACBFF), Amgen (AMGN), Amarin (AMRN) and Aphria (APHQF).
What is Propanc Biopharma's stock symbol?: Propanc Biopharma trades on the OTCMKTS under the ticker symbol "PPCB."

How do I buy shares of Propanc Biopharma?: Shares of PPCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Propanc Biopharma's stock price today?: One share of PPCB stock can currently be purchased for approximately $0.03.
How much money does Propanc Biopharma make?: Propanc Biopharma (OTCMKTS:PPCB) has a market capitalization of $88,447.20.
How can I contact Propanc Biopharma?: Propanc Biopharma's mailing address is 302/6 BUTLER STREET VICTORIA, CAMBERWELL C3, 3124. The official website for the company is www.propanc.com. The company can be reached via phone at (139) 882-0780, via email at irteam@propanc.com, or via fax at 61 03 9882 9969.

This page (OTCMKTS:PPCB) was last updated on 9/21/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial